Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Cash from Financing Activities: 2017-2025

Historic Cash from Financing Activities for Dianthus Therapeutics (DNTH) over the last 4 years, with Sep 2025 value amounting to $274.5 million.

  • Dianthus Therapeutics' Cash from Financing Activities rose 92640.88% to $274.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $314.9 million, marking a year-over-year increase of 49.19%. This contributed to the annual value of $255.6 million for FY2024, which is 91.37% up from last year.
  • Per Dianthus Therapeutics' latest filing, its Cash from Financing Activities stood at $274.5 million for Q3 2025, which was up 48,229.75% from $568,000 recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Cash from Financing Activities ranged from a high of $274.5 million in Q3 2025 and a low of -$4.9 million during Q4 2023.
  • Moreover, its 3-year median value for Cash from Financing Activities was $568,000 (2025), whereas its average is $73.8 million.
  • Examining YoY changes over the last 5 years, Dianthus Therapeutics' Cash from Financing Activities showed a top increase of 92,640.88% in 2025 and a maximum decrease of 99.93% in 2025.
  • Quarterly analysis of 4 years shows Dianthus Therapeutics' Cash from Financing Activities stood at $96.6 million in 2022, then spiked by 43.27% to -$4.9 million in 2023, then surged by 915.54% to $39.7 million in 2024, then skyrocketed by 92,640.88% to $274.5 million in 2025.
  • Its last three reported values are $274.5 million in Q3 2025, $568,000 for Q2 2025, and $161,000 during Q1 2025.